A randomized, double-blind, placebo-controlled trial with Probi’s two probiotic strains, HEAL9TM and LP6595, was shown to reduce gastrointestinal problems for women receiving pelvic radiotherapy.
The 3-armed study included 75 women with gynecological cancer receiving pelvic radiotherapy. The patients were either given a high or a low dose of the combined probiotic strains HEAL9TM and LP6595 or placebo and was conducted on two sites in Sweden.
“When receiving radiotherapy in connection with gynecological cancer, women often experience gastrointestinal problems during and after the therapy. This study showed significantly reduced severity and frequency of both abdominal pain and defecation urgency,” explains Niklas Larsson, Senior Director Scientific Affairs & IP at Probi.
“It is extremely rewarding to see that such a vulnerable group may be helped in a very exposed situation by consuming our probiotic strains. This is completely in line with our vision to provide probiotics for healthier lives by being an innovative frontrunner,” says Tom Rönnlund, CEO at Probi.
The study “Decreasing the Adverse Effects in Pelvic Radiation Therapy: A Randomized Controlled Trial Evaluating the Use of Probiotics” was recently published in Advances in Radiation Oncology (2022) 8, 101089 and can be found here: https://doi.org/10.1016/j.adro.2022.101089
Innovations in Food (& Beverage) Technology is a quarterly magazine distributed globally both in Print and Digital formats. www.innovationsfood.com. Twitter: @Innovfoodtech. Instagram: @innovationsinfoodtechnology. Linkedin: www.linkedin.com/in/terry-prior52
